Patent ID: 8883855
Filing Date: 2014-11-11
Classification: A61K,A61P

Abstract:
1. A method of treating cognitive impairment caused by chemotherapy induced demyelination in a human subject comprising the steps of: identifying a subject in need for treatment of cognitive impairment due to demyelination after completion of chemotherapy, wherein the patient has one or more symptoms selected from confusion, forgetfulness, difficulty in concentration, or maintenance of focus; and administering a pharmaceutical composition comprising N-2-hydroxy-ethyl-piperazine-N′-2-ethane sulfonic acid (HEPES) and derivatives thereof dissolved in sterile water, buffer, saline or other pharmaceutically acceptable carriers once daily at a dosage of 10-100 mg/kg of body weight, wherein the pharmaceutical composition is administered orally, subcutaneously, parenterally, intravenously, peritoneally, or intramuscularly, wherein the amount is sufficient to treat the one or more symptoms.